Matching articles for "Synjardy"
Empagliflozin (Jardiance) for Type 2 Diabetes in Children (online only)
The Medical Letter on Drugs and Therapeutics • August 21, 2023; (Issue 1683)
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor empagliflozin has been available for years
alone (Jardiance – Boehringer Ingelheim) and in
combination with metformin (Synjardy) to improve
glycemic...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor empagliflozin has been available for years
alone (Jardiance – Boehringer Ingelheim) and in
combination with metformin (Synjardy) to improve
glycemic control in adults with type 2 diabetes. Both
products have now been approved for use in children
≥10 years old. Empagliflozin is the second oral drug
to become available in the US for treatment of type
2 diabetes in children; metformin has been available
since 2000 for this indication. The injectable
glucagon-like peptide-1 (GLP-1) receptor agonists
liraglutide (Victoza) and extended-release exenatide
(Bydureon BCise) are also approved for use in children
≥10 years old.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 14, 2022; (Issue 1663)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.
Comparison Chart: SGLT2 Inhibitors (online only)
The Medical Letter on Drugs and Therapeutics • November 16, 2020; (Issue 1611)
...
View the Comparison Chart: SGLT2 Inhibitors
In Brief: Trijardy XR - A New 3-Drug Combination for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • June 1, 2020; (Issue 1599)
The FDA has approved Trijardy XR (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose
cotransporter 2 (SGLT2) inhibitor empagliflozin, the
dipeptidyl peptidase-4 (DPP-4) inhibitor...
The FDA has approved Trijardy XR (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose
cotransporter 2 (SGLT2) inhibitor empagliflozin, the
dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, and
extended-release metformin, for oral treatment of type 2
diabetes in adults. Empagliflozin and linagliptin have been
available in a fixed-dose combination as Glyxambi since
2015, and both have been available in 2-drug combinations
with extended-release metformin for years (see Table 1).
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 4, 2019; (Issue 1584)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of <7% can prevent
microvascular complications (retinopathy, nephropathy,
and neuropathy), but whether it prevents macrovascular
complications and death is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease (CVD), a history
of severe hypoglycemia, diabetes-related complications,
a limited life expectancy, or a long duration of disease.
Ertugliflozin for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • April 23, 2018; (Issue 1545)
The FDA has approved the sodium-glucose co-transporter
2 (SGLT2) inhibitor ertugliflozin (Merck)
for treatment of adults with type 2 diabetes, both
alone (Steglatro) and in fixed-dose combinations
with...
The FDA has approved the sodium-glucose co-transporter
2 (SGLT2) inhibitor ertugliflozin (Merck)
for treatment of adults with type 2 diabetes, both
alone (Steglatro) and in fixed-dose combinations
with metformin (Segluromet) and sitagliptin
(Steglujan). Ertugliflozin is the fourth SGLT2 inhibitor
to be approved in the US. All four are available in
combination with metformin and three are available
in combination with a dipeptidyl peptidase-4 (DPP-4)
inhibitor (see Table 3).
Comparison Table: SGLT2 Inhibitors (online only)
The Medical Letter on Drugs and Therapeutics • January 30, 2017; (Issue 1513)
...
View the Comparison Table: SGLT2 Inhibitors
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 16, 2017; (Issue 1512)
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating...
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating to this target has been shown to
prevent microvascular complications (retinopathy,
nephropathy, and neuropathy), but whether it prevents
macrovascular outcomes is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease, a history of
severe hypoglycemia, diabetes-related complications
or comorbidities, or a long duration of disease.
Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • December 21, 2015; (Issue 1484)
The FDA has approved Synjardy (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose
co-transporter 2 (SGLT2) inhibitor empagliflozin
(Jardiance) and metformin (Glucophage, and...
The FDA has approved Synjardy (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose
co-transporter 2 (SGLT2) inhibitor empagliflozin
(Jardiance) and metformin (Glucophage, and others),
for treatment of patients with type 2 diabetes not
adequately controlled on either of these drugs alone
or already being treated with both empagliflozin and
metformin. It is the third SGLT2 inhibitor/metformin
combination to be approved in the US.